Vyvgart Iv MG denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Vyvgart IV for Myasthenia Gravis as Experimental — and Why That Is Wrong

Vyvgart (efgartigimod alfa, intravenous formulation) carries FDA approval for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. A denial characterizing an FDA-approved therapy used for its approved indication as "experimental" or "investigational" is factually incorrect and is among the most clearly reversible denial types. This denial pattern typically arises from outdated plan coverage policies that have not been updated to reflect the FDA approval, or from reviewer error.

## Why This Denial Is Immediately and Strongly Appealable

FDA approval is the regulatory determination that a therapy is safe and effective for its approved use — the opposite of experimental. UHC's own coverage policies generally define "experimental" to exclude FDA-approved therapies used within their approved indications. The appeal can lead with the FDA approval documentation and UHC's own policy language to demonstrate the internal contradiction in the denial.

## Federal Appeal Framework

• Internal appeal: ACA §2719 and ERISA §503 guarantee a full-and-fair review. Submit immediately with the FDA approval documentation. Regulatory deadlines are typically 30 days for pre-service decisions.
• External review: If the internal appeal is denied despite clear FDA approval evidence, escalate to independent external review. The external reviewer — an independent clinical organization — will see the same FDA evidence. File within the window on the denial notice (often around four months from the final internal denial).
• Expedited review: Request if the patient's gMG is severe or unstable and delay poses serious health risk, including respiratory compromise.
• State Insurance Commissioner: Persistent denial of an FDA-approved therapy for its approved indication may constitute a coverage violation warranting a regulatory complaint.

## Documentation to Gather

1. FDA prescribing information — the current Vyvgart label from Drugs@FDA, citing the approved indication that matches the patient's diagnosis. 2. Anti-AChR antibody status — lab documentation confirming the patient is antibody-positive, consistent with the FDA-approved indication. 3. gMG diagnosis confirmation — neurology records establishing the generalized MG diagnosis. 4. UHC coverage policy — pull the current UHC medical policy defining "experimental/investigational" to show the FDA-approved therapy falls outside that definition. 5. Prescriber letter — confirming the drug is being used for its FDA-approved indication in an FDA-eligible patient.

## Criteria-Mapping Structure

Your appeal should include a two-column table: (1) UHC's definition of experimental/investigational from the current policy, and (2) the FDA approval facts that demonstrate the therapy does not meet that definition. Then address any secondary criteria in the UHC coverage policy. Source all definitions and criteria from the FDA label and the current UHC policy — not from memory.